TGFB1 and non-small cell lung carcinoma: demonstrated that in patients with stage III NSCLC who underwent 3D-CRT, circulating TGF-β1 levels increased during the first 2 weeks after the first fraction of RT and were significantly increased at week 6 in the patients who developed RILI (grade ≥1) (53).